Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Non-cash Items (2017 - 2025)

Spero Therapeutics' Non-cash Items history spans 9 years, with the latest figure at $58000.0 for Q4 2025.

  • For Q4 2025, Non-cash Items changed N/A year-over-year to $58000.0; the TTM value through Dec 2025 reached $58000.0, changed N/A, while the annual FY2025 figure was $58000.0, N/A changed from the prior year.
  • Non-cash Items reached $58000.0 in Q4 2025 per SPRO's latest filing, down from $2.4 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $33.2 million in Q3 2021 to a low of $1000.0 in Q4 2022.
  • Average Non-cash Items over 5 years is $6.4 million, with a median of $2.5 million recorded in 2024.
  • Peak YoY movement for Non-cash Items: tumbled 100.0% in 2022, then surged 261444.0% in 2024.
  • A 5-year view of Non-cash Items shows it stood at $24.3 million in 2021, then crashed by 100.0% to $1000.0 in 2022, then changed by 0.0% to $1000.0 in 2023, then soared by 261444.0% to $2.6 million in 2024, then plummeted by 97.78% to $58000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Non-cash Items are $58000.0 (Q4 2025), $2.4 million (Q3 2025), and $2.5 million (Q2 2025).